Zevra to face FDA adcomm in August over previously rejected rare disease drug
The FDA’s recently created Genetic Metabolic Diseases Advisory Committee will meet on Aug. 2 to review Zevra Therapeutics’ arimoclomol as a treatment for the rare …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
